EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Rituximab for the treatment of refractory immune thrombocytopenic purpura - Case report



Rituximab for the treatment of refractory immune thrombocytopenic purpura - Case report



Blood 94(10 SUPPL 1 PART 2): 82b, Nov 15




(PDF emailed within 1 workday: $29.90)

Accession: 035674792

Download citation: RISBibTeXText



Related references

Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. American Journal of Hematology 78(1): 49-54, 2004

A combination of bortezomib and rituximab yields a dramatic response in a woman with highly refractory immune thrombocytopenic purpura: a case report. Journal of Medical Case Reports 8: 19-19, 2014

Case report; successful treatment with rituximab in a patient with refractory thrombotic thrombocytopenic purpura. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 102(1): 147-149, 2013

Successful treatment of idiopathic acquired refractory thrombotic thrombocytopenic purpura with an association of rituximab-vindesine. Report of one case. Revista Medica de Chile 133(11): 1349-1354, 2006

Rituximab is effective in the treatment of refractory immune thrombocytopenic purpura associated with chronic lymphocytic leukemia. Southern Medical Journal 98(12): 1227-1228, 2006

Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura. Southern Medical Journal 95(10): 1209-1212, 2002

Combination therapy of rituximab and corticosteroids for patients with refractory chronic immune thrombocytopenic purpura: report of two cases. Contemporary Oncology 17(2): 222-224, 2013

Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab. Journal of Clinical Pathology 60(6): 715-716, 2007

Treatment of an infant with severe acute refractory immune thrombocytopenic purpura using combination therapy including rituximab. Pediatric Blood & Cancer 53(2): 203-205, 2009

Refractory thrombotic thrombocytopenic purpura associated with primary Sjogren syndrome treated with rituximab: a case report. American Journal of Therapeutics 21(2): E56-E60, 2014

Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Swiss Medical Weekly 137(37-38): 518-524, 2007

Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. International Journal of Hematology 84(1): 48-53, 2006

Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. European Journal of Haematology 83(4): 365-372, 2009

Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura. Journal of Obstetrics and Gynaecology Canada 32(12): 1167-1171, 2011

Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura. Internal Medicine Journal 41(2): 202-205, 2013